Physician profile
Tiffany Masters Redfern
NPI 1679984363
$165,071.93
in general payments reported to CMS, 2019-2025
34 companies · $82K in 2025
The $82K reported for 2025 was more than what 98% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $340 · 2021: $317 · 2022: $1,344 · 2023: $24K · 2024: $57K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Travel and Lodging: $25K · Consulting Fee: $18K · Food and Beverage: $8,591 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,875.00 |
| Travel and Lodging | $24,633.13 |
| Consulting Fee | $18,348.50 |
| Food and Beverage | $8,590.53 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $81,602.16 | 2022-2025 | Tivdak, Epkinly |
| Abbvie INC. | $30,908.71 | 2024-2025 | |
| Pfizer INC. | $21,433.46 | 2024-2025 | |
| Seagen INC. | $12,425.50 | 2023 | Tivdak |
| Daiichi Sankyo INC. | $5,077.37 | 2023-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $4,125.79 | 2020-2025 | Keytruda, Lynparza |
| Intuitive Surgical, INC. | $2,452.30 | 2022-2023 | Da Vinci Surgical System |
| Eisai INC. | $2,423.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,416.09 | 2019-2025 | Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $538.86 | 2020-2025 | Jemperli, Zejula |
| Ethicon US, LLC | $422.06 | 2019-2023 | Enseal |
| Stryker Corporation | $314.52 | 2021-2024 | 1788 |
| Immunogen, INC. | $242.69 | 2023-2024 | Elahere, Elahere |
| Clovis Oncology, INC. | $238.87 | 2019-2020 | |
| Medtronic, INC. | $168.37 | 2021-2025 | Truclear |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $136.68 | 2025 | Korlym |
| On Target Laboratories, INC | $130.46 | 2025 | Cytalux |
| Incyte Corporation | $124.99 | 2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $121.86 | 2023 | Opdivo |
| Menarini Silicon Biosystems, INC. | $117.12 | 2023 | Cellsearch |
| Tesaro, INC. | $111.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $85.59 | 2023-2024 | |
| Becton, Dickinson and Company | $85.49 | 2024 | Arista Ah Flexitip |
| Integra Lifesciences Corporation | $85.40 | 2021-2023 | Codman Certas, Duraseal Exact Spinal Sealant System, Codman Hakim |
| Dilon Technologies, INC. | $48.63 | 2025 | Hemoblast Bellows |
| Myriad Genetic Laboratories, INC. | $42.64 | 2024 | Myrisk |
| Astellas Pharma US INC | $40.39 | 2023-2024 | Veozah |
| Foundation Medicine, INC. | $28.00 | 2023 | |
| Servier Pharmaceuticals LLC | $24.90 | 2024 | |
| Gilead Sciences, INC. | $23.68 | 2023 | Trodelvy |
| Springworks Therapeutics, INC. | $22.63 | 2024 | Ogsiveo |
| Acrotech Biopharma INC. | $17.75 | 2023 | Beleodaq |
| Kyowa Kirin, INC. | $17.65 | 2019 | |
| Fennec Pharmaceuticals, INC. | $16.03 | 2024 | Pedmark |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Redfern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.